Remdesivir for COVID-19 linked to better outcomes for adult kidney transplant recipients

Adults with kidney transplants who were treated for COVID-19 with the antiviral remdesivir within a week of a COVID-19 diagnosis and who received at least three consecutive days of therapy were less likely than kidney transplant recipients who did not receive the antiviral to experience cardiovascular or kidney problems up to a year later, according to findings from a target trial emulation study published in JAMA Network Open. ...